Clinical Trials Database

Protocol	Title
Breast (DCIS)	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER-2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
Colorectal (Metastatic)	A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination with mFOLFOX6 to the Efficacy of Bevacizumab in Combination with mFOLFOX6 in Patients with Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer.
Non Small Cell Lung (Adjuvant)	Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology.
Non Small Cell Lung (Newly Diagnosed Metastatic)	Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology
Non-Small Cell Lung (Supportive Care)	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
ITP	A multi-center, prospective, open-label, clinical trial to assess the safety and the efficacy of a new intravenous immune globulin (IGIV3I Grifols 10%) in patients with idiopathic (immune) thrombocytopenic purpura.
ITP	A Prospective, Phase IV, Open-label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Venous Thromboembolism	Dalteparin Sodium Injection (FRAGMIN®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism.